Moderate to Severe Asthma
Conditions
Brief summary
This is a Phase Ib study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, immunogenicity and preliminary efficacy of RC1416 injection in patients with moderate to severe asthma.
Detailed description
This study is a randomized, double-blind, placebo-controlled, ascending dose Phase Ib clinical study. RC1416 is a bispecific antibodies .It is being developed by Nanjing RegeneCore Biotech Co., Ltd. as a potential therapy for asthma. A total 40 patients with moderate to severe asthma will be enrolled in 4 groups to access the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of RC1416 injection.
Interventions
DRUGRC1416
there are four doses(200mg-400mg) in this part. Each subjects will receive the drug once by subcutaneous injection.
DRUGRC1416 Placebo
Each subjects will receive the placebo once by subcutaneous injection.
Sponsors
Nanjing RegeneCore Biotech Co., Ltd.
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
1. The subject fully understands the purpose, nature, methods and potential adverse events of the trial and voluntarily signs the informed consent form (ICF); 2. Male or female patients aged ≥18 and ≤75 years at the time of ICF signing; 3. The subject has been diagnosed with asthma for at least one year; 4. The subject has been treated with medium to high-dose inhaled corticosteroids (ICS) (e.g.,fluticasone propionate ≥ 250 μg daily or equivalent ICS dose) in combination with at least one additional controller medication \[such as long-acting β2 receptor agonists (LABA), long-acting anticholinergic drugs (LAMA), leukotriene receptor antagonists (LTRA), or sustained-release theophylline\] for ≥ 3 months prior to ICF signing, with a stable dosing for ≥ 1 month before randomization; 5. ACQ-6 score \> 1.5 or ACT score \< 20 ; 6. Pre-bronchodilator FEV1 ≤ 80% of predicted value at screening; 7. Positive objective tests for variable airflow obstruction within one year before randomization or during the screening period (including bronchodilation test, bronchial provocation test or peak expiratory flow variability, etc.). 8. The subject agrees to take effective contraceptive measures (as specified in the protocol) from the time of ICF signing until 6 months post-treatment.
Exclusion criteria
1. Based on the investigator's judgment,Clinically diagnosed with chronic obstructive pulmonary disease (COPD) or other lung diseases that may significantly impair lung function (such as atelectasis, pulmonary fibrosis, bronchopulmonary dysplasia, bronchiectasis, emphysema, etc.) ; 2. Subjects who had required at least one systemic glucocorticoid treatment due to asthma exacerbation or other reasons, or who had been hospitalized or treated emergency department due to asthma exacerbation within one month before administration; 3. Subjects with a history of near-fatal asthma requiring endotracheal intubation and mechanical ventilation; 4. Subjects who are Excessive dependence on short-acting β-agonists (SABA) (\>10-12 puffs per day) , especially use more than one vial of salbutamol (or equivalent) per month; 5. Subjects who used non-selective β-blockers within 1 month before screening until randomization; 6. Subjects with pulmonary or other infection and oral or intravenous antibiotics or antifungal or antiviral drugs within one month before administration; Subjects have need local antibiotic or antiviral treatment within 7 days before screening;Subjects with a history of recurrent infections (≥3 times per year) and underlying diseases that predispose to infection; Subjects with a history of disseminated herpes simplex infection or recurrent (\>1 time) or disseminated herpes zoster; Subjects with a history of opportunistic infections; 7. Subjects who underwent major surgery within 6 months prior to screening or planned major surgery during the trial. 8. Subjects who have suffered form malignancy within 5 years,except: * Subjects with cervical carcinoma in situ that has been completely resected and has no evidence of recurrence or metastasis for at least 3 years; * Subjects with basal cell or squamous cell carcinoma that have been completely resected and have no recurrence for at least 3 years; * Subjects with a history of cancer who have had complete remission of their malignant tumors for at least 5 years at the time of screening and have no anti-tumor treatment; 9. Currently receiving or having received any of the prohibited drugs or treatments in this trial within the following time frames : 1. Live vaccines, attenuated live vaccines, or adenovirus vector vaccines within 3 months prior to screening or plan to receive such vaccines during the trial; 2. Any of the following drugs within 3 months or 5 half-lives (whichever is longer) prior to screening: IL-4Rα antagonists, IL-5/interleukin-5 receptor (IL-5R) antagonists, anti-IgE monoclonal antibodies, anti-TSLP antibodies, etc.; 3. Bronchial thermoplasty within 3 years prior to screening; 4. Allergen immunotherapy within 3 months prior to screening or plan to receive such treatments during the trial; 5. Drugs that affect immunity within 3 months or 5 half-lives (whichever is longer) prior to screening, including but not limited to systemic immunosuppressants/immunomodulatory drugs (including but not limited to methotrexate, cyclosporine, etc.); 6. Montelukast within 2 weeks prior to screening; 7. Immunoglobulin products within 3 months prior to screening; 8. Traditional Chinese medicine or herbal products that affect bronchospasm and/or lung function within 1 month prior to screening. 10. Subjects who have received any investigational drug or participated in other clinical trials or medical research activities within 3 months or 5 half-lives (whichever is longer) before screening, or plan to participate in other drug or medical device clinical trials during the trial; except subjects who have only signed the ICF and participated in the screening of clinical trials but did not receive clinical trial treatment or enrollment within 3 months before the first dose. 11. Subjects who have donated blood or lost blood ≥ 400 mL (excluding menstrual blood loss), or received blood transfusion or used blood products within 3 months before screening, or plan to donate blood during the study or within 1 month after the end of the trial. 12. Current smokers or subjects who quit smoking within 6 months before screening, or previous smokers who quit smoking more than 6 months at screening with a smoking history \> 10 pack-years (pack-years = number of packs smoked per day × number of years of smoking, 20 cigarettes per pack), or who cannot quit smoking during the trial. 13. Subjects with known to be allergy to the excipients or ingredients of this product, or have had severe drug or food allergic reactions in the past. 14. With any psychological disorders or neurological/psychiatric disorders confirmed by the investigator. 15. Subjects who have difficulty with venous blood collection,or are afraid of needles or blood, or those who have difficulty with subcutaneous injection administration. 16. Any of the following abnormal in laboratory test results at screening or baseline: 1. Hemoglobin \< 90 g/L; 2. Platelet count \< 100 × 109/L; 3. Absolute neutrophil count (ANC) \< 1.2 × 109/L; 4. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \> 2.5 × ULN (upper limit of normal); 5. Serum creatinine \> 1.5 × ULN; 6. Total bilirubin \> 1.5 × ULN; 7. Other laboratory test results abnormalities are clinically significant, and the investigator judge that the subject are unsuitable for enrollment. 17. Subject with clinically significant abnormalities in the 12-lead ECG at screening or baseline as judged by the investigator , or prolonged QTc ( QTcF interval \>450 ms for males and \>470 ms for females, Corrected by Fridericia，s formula), or a history of long QT syndrome. 18. Any one of infectious disease screening indicators meets the following criteria at screening: 1. According to the judgment of the investigator, there is vidence of active tuberculosis or a history of active tuberculosis without appropriate treatment, and screening results suggest the possibility of latent tuberculosis infection as judged by the investigator; 2. Positive for hepatitis B surface antigen (HBsAg), or positive for hepatitis B core antibody (HBcAb) and hepatitis B virus deoxyribonucleic acid (HBV DNA) exceeds the detection limit; 3. Hepatitis C antibody (HCVAb) positive and hepatitis C virus ribonucleic acid (HCV RNA) exceeds the detection limit; 4. Positive for Treponema pallidum (Tp) antibody; 5. Positive for human immunodeficiency virus antigen (HIVAg) or human immunodeficiency virus antibody (HIVAb). 19. Subject with previous history of drug abuse/drug use； 20. Subject with a history of alcoholism within 6 months prior to screening\[(i.e., more than 14 standard units per week for women and more than 21 standard units per week for men (1 standard unit containing 14g of alcohol, such as 360 mL beer or 45 mL spirits with 40% alcohol or 150 mL wine) \]or those who cannot abstinence during the trial; 21. Pregnant or lactating women, or those with a positive pregnancy test result; 22. Other situations that the investigator judged are unsuitable for participating in this trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| AE | up to 141 days | incidence ,severity and relation to investigational drugs of Adverse Events according to CTCAE V5.0 |
| SAE | up to 141 days | incidence ,severity and relation to investigational drugs of Adverse Events according to CTCAE V5.0 |
| Vital Signs | up to 141 days | number of praticipants with clinically notable Vital Signs according to CTCAE V5.0 |
| Laboratory Tests | up to 141 days | number of praticipants with clinically Laboratory Tests Values according to CTCAE V5.0 |
| ECG | up to 141 days | number of praticipants with clinically notable Electrocardiogram(ECG) Values according to CTCAE V5.0 |
| Injection Site Reaction | up to 85 days | number of praticipants with clinically notable Injection Site Reaction according to CTCAE V5.0 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cmax | up to 141 days | maximum serum concentration |
| AUC0-t | up to 141 days | AUC extrapolated to infinitymeasurable concentration |
| AUC0-inf | up to 141 days | area under the concentration-time curve (AUC) from administration to the last measurable concentration |
| Anti-Drug antibody (ADA) | up to 141 days | number and percentage of subjects tested ADA positive |
| Tmax | up to 141 days | time to reach maximum concentration |
| t1/2 | up to 141 days | the terminal elimination half-life |
| MRT | up to 141 days | mean residence time |
| λz | up to 141 days | elimination rate constant |
| CL/F | up to 141 days | apparent clearance |
| Vz/F | up to 141 days | apparent volume of distribution |
| Change from baseline in fractional exhaled nitric oxide (FeNO) | up to 141 days | Preliminary effectiveness indicators |
| Change from baseline in total IgE (immunoglobulin E), human thymus and activation-regulated chemokine (TARC) | up to 141 days | Preliminary effectiveness indicators |
| Change from baseline in blood eosinophil (EOS) count, free or bound IL-5 and total IL-5, and free IL-4 and IL-13 levels | up to 141 days | Preliminary effectiveness indicators |
Countries
China
Outcome results
None listed